Shanghai InnoStar Bio-tech Co. Ltd. Class A

As of June 30, 2026, Shanghai InnoStar Bio-tech Co. Ltd. Class A carries a market capitalization of 9.47B, placing it among publicly traded companies globally. Its enterprise value stands at 8.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai InnoStar Bio-tech Co. Ltd. Class A's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Shanghai InnoStar Bio-tech Co. Ltd. Class A has 140.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai InnoStar Bio-tech Co. Ltd. Class A maintains a current ratio of 2.28, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai InnoStar Bio-tech Co. Ltd. Class A recorded 789,355.03 in income tax expense.

As of the close on October 22, 2026, Shanghai InnoStar Bio-tech Co. Ltd. Class A's stock has gained approximately 95.69% over the past 52 weeks. The 50-day moving average sits at 90.56, while the 200-day moving average is 69.42.

As of June 30, 2026, Shanghai InnoStar Bio-tech Co. Ltd. Class A holds 1.49B in cash and equivalents against 130.26M in total debt, resulting in a net debt position of -1.49B. Total book value stands at 2.37B, with working capital of 1.46B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.